Drug Database
Back to search

Poland· PL-100464349

Paxlovid

A nirmatrelvir und ritonavir product containing nirmatrelvirum + ritonavirum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 11 of our 19 countries.

ATC J05AE30

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPaxlovidATCJ05AE30REGISTER NO.PL-100464349PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nirmatrelvirum + ritonavirumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nirmatrelvir und ritonavir is registered in 11 of 19 countries.

Countries holding a registration under ATC J05AE30 (nirmatrelvir und ritonavir), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search nirmatrelvir und ritonavir products by name

Nirmatrelvir und ritonavir · ATC J05AE30

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nirmatrelvir und ritonavir costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Nirmatrelvir und ritonavir · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$851.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Nirmatrelvirum + Ritonavirum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
J05AE30
ATC class
Nirmatrelvir und Ritonavir
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05415062386538

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for nirmatrelvir und ritonavir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nirmatrelvir und ritonavir against other medicinesHow interaction checks work

Nirmatrelvir und ritonavir · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Nirmatrelvir und ritonavir in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nirmatrelvir und ritonavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Paxlovid
  • Liechtenstein · Paxlovid
  • Norway · Paxlovid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/11abd9ab-f064-4051-b236-e82a09b34ff3
GET /v1/drugs/11abd9ab-f064-4051-b236-e82a09b34ff3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg + 100 mg",
  "packaging": "05415062386538 ¦ Rp ¦ EU/1/22/1625/001 ¦ 143778\n20 tabl. 150 mg nirmatrelwiru ¦ 10 tabl. 100 mg rytonawiru",
  "substance": "Nirmatrelvirum 150 mg + Ritonavirum 100 mg",
  "common_name": "Nirmatrelvirum + Ritonavirum",
  "pl_product_id": "100464349",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about nirmatrelvir und ritonavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console